Beactica Therapeutics Participates in Innovative Training Network on Targeted Protein Degradation
Retrieved on:
Wednesday, October 30, 2019
UPPSALA, Sweden, Oct. 30, 2019 /PRNewswire/ -- Beactica Therapeutics, the Swedish drug discovery company, today announced its participation in a Marie Skodowska-Curie Innovative Training Network (ITN) called UbiMotif.
Key Points:
- UPPSALA, Sweden, Oct. 30, 2019 /PRNewswire/ -- Beactica Therapeutics, the Swedish drug discovery company, today announced its participation in a Marie Skodowska-Curie Innovative Training Network (ITN) called UbiMotif.
- Pioneering early clinical data presented just this year show that targeted protein degradation has the potential to create safe and well-tolerated orally bioavailable drugs, so called proteolysis-targeting chimeras (PROTACs).
- Beactica has developed its own PROTACs-enabling technology to broaden its pipeline of first-in-class therapeutics.
- said Dr Per Kllblad, CEO of Beactica Therapeutics, "Training a new generation of drug hunters is essential to the future of the sector as well as Beactica's growth".